Press Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Like
Comment
Favorite

Press Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Dow Jones2024-11-14

Operating loss         11,328       7,795       27,838      20,076 
 
Other income              (84)        (89)      (2,189)       (270) 
Interest expenses           5         574          868       1,884 
Income from 
 change in fair 
 value of Private 
 Placement 
 Warrants             (20,559)          -      (24,417)          - 
Finance expense 
 (income), net           (332)       (382)       1,104      (1,034) 
                   ----------   ---------   ----------   --------- 
 
Loss (income) 
 before tax            (9,642)      7,898        3,204      20,656 
 
Tax expenses                -           8           10          22 
 
Net loss (income)      (9,642)      7,906        3,214      20,678 
 
Basic loss 
 (earnings) per 
 share of Common 
 Stock (*)              (0.31)       1.30         0.32        4.29 
Diluted loss per 
 share of Common 
 Stock (*)              (0.31)       1.30         2.45        4.29 
 
Weighted average 
 number of shares 
 used in 
 computing basic 
 loss (earnings) 
 per share of 
 Common Stock      16,366,122   6,058,774    9,944,267   4,819,658 
                   ==========   =========   ==========   ========= 
Weighted average 
 number of shares 
 used in 
 computing 
 diluted loss per 
 share of Common 
 Stock             16,387,633   6,058,774   11,294,879   4,819,658 
                   ==========   =========   ==========   =========

(END) Dow Jones Newswires

November 14, 2024 06:30 ET (11:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

05:35
Welspun Enterprises Ltd - Approved Sale of Its Entire Stake in Kim Mandvi Corridor
05:33
PPC Ltd - Board Approves R3 Billion Cement Plant in Western Cape
05:32
Steel Strips Wheels Ltd - Says No Effect on Product Due to Tariff
05:31
Formycon Ag - Currently Expects That a Positive Ebitda Can Ideally Be Achieved as Early as 2026, but No Later Than 2027
05:31
Formycon Ag - Expects Ebitda for 2025 Financial Year to Be in Range of EUR -10.0 Mln to EUR -20.0 Mln

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2483298878?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-14 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483298878","market":"nz","top_or_hot":-1,"title":"Press Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\nOperating loss         11,328       7,795       27,838      20,076 \n \nOther income              (84)        (89)      (2,189)       (270) \nInterest expenses           5         574          868       1,884 \nIncome from \n change in fair \n value of Private \n Placement \n Warrants             (20,559)          -      (24,417)          - \nFinance expense \n (income), net           (332)       (382)       1,104      (1,034) \n                   ----------   ---------   ----------   --------- \n \nLoss (income) \n before tax            (9,642)      7,898        3,204      20,656 \n \nTax expenses                -           8           10          22 \n \nNet loss (income)      (9,642)      7,906        3,214      20,678 \n \nBasic loss \n (earnings) per \n share of Common \n Stock (*)              (0.31)       1.30         0.32        4.29 \nDiluted loss per \n share of Common \n Stock (*)              (0.31)       1.30         2.45        4.29 \n \nWeighted average \n number of shares \n used in \n computing basic \n loss (earnings) \n per share of \n Common Stock      16,366,122   6,058,774    9,944,267   4,819,658 \n                   ==========   =========   ==========   ========= \nWeighted average \n number of shares \n used in \n computing \n diluted loss per \n share of Common \n Stock             16,387,633   6,058,774   11,294,879   4,819,658 \n                   ==========   =========   ==========   ========= \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2024 06:30 ET (11:30 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-14 19:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\nOperating loss         11,328       7,795       27,838      20,076 \n \nOther income              (84)        (89)      (2,189)       (270) \nInterest expenses           5         574          868       1,884 \nIncome from \n change in fair \n value of Private \n Placement \n Warrants             (20,559)          -      (24,417)          - \nFinance expense \n (income), net           (332)       (382)       1,104      (1,034) \n                   ----------   ---------   ----------   --------- \n \nLoss (income) \n before tax            (9,642)      7,898        3,204      20,656 \n \nTax expenses                -           8           10          22 \n \nNet loss (income)      (9,642)      7,906        3,214      20,678 \n \nBasic loss \n (earnings) per \n share of Common \n Stock (*)              (0.31)       1.30         0.32        4.29 \nDiluted loss per \n share of Common \n Stock (*)              (0.31)       1.30         2.45        4.29 \n \nWeighted average \n number of shares \n used in \n computing basic \n loss (earnings) \n per share of \n Common Stock      16,366,122   6,058,774    9,944,267   4,819,658 \n                   ==========   =========   ==========   ========= \nWeighted average \n number of shares \n used in \n computing \n diluted loss per \n share of Common \n Stock             16,387,633   6,058,774   11,294,879   4,819,658 \n                   ==========   =========   ==========   ========= \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 14, 2024 06:30 ET (11:30 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483298878","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483298878","pubTimestamp":1731583800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis  patient enrollment completed and on track to report topline results in Q1 2025. BX004 Phase 2b study in Cystic Fibrosis  is now expected to report topline results in H1 2026 following resolved manufacturing delays. NESS ZIONA, Israel, Nov. 14, 2024  -- BiomX Inc. , a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announces financial results for its third quarter ended September 30, 2024, and provides program and business updates.received towards this trial has totaled $36.8 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"新闻稿：BiomX公布2024年第三季度财务业绩并提供业务和计划更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CF":1,"PHGE":0.9},"content_text":"Operating loss         11,328       7,795       27,838      20,076 \n \nOther income              (84)        (89)      (2,189)       (270) \nInterest expenses           5         574          868       1,884 \nIncome from \n change in fair \n value of Private \n Placement \n Warrants             (20,559)          -      (24,417)          - \nFinance expense \n (income), net           (332)       (382)       1,104      (1,034) \n                   ----------   ---------   ----------   --------- \n \nLoss (income) \n before tax            (9,642)      7,898        3,204      20,656 \n \nTax expenses                -           8           10          22 \n \nNet loss (income)      (9,642)      7,906        3,214      20,678 \n \nBasic loss \n (earnings) per \n share of Common \n Stock (*)              (0.31)       1.30         0.32        4.29 \nDiluted loss per \n share of Common \n Stock (*)              (0.31)       1.30         2.45        4.29 \n \nWeighted average \n number of shares \n used in \n computing basic \n loss (earnings) \n per share of \n Common Stock      16,366,122   6,058,774    9,944,267   4,819,658 \n                   ==========   =========   ==========   ========= \nWeighted average \n number of shares \n used in \n computing \n diluted loss per \n share of Common \n Stock             16,387,633   6,058,774   11,294,879   4,819,658 \n                   ==========   =========   ==========   ========= \n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 06:30 ET (11:30 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}